Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $7.25B | $7.96B | $9.65B | $12.4B |
| Revenue growth | — | 9.8% | 21.2% | 28.5% |
| Gross profit | $650M | $754M | $1.03B | $1.49B |
| Gross margin | 9.0% | 9.5% | 10.7% | 12.1% |
| Operating income | $289M | $338M | $599M | $1.04B |
| Operating margin | 4.0% | 4.2% | 6.2% | 8.4% |
| Net income | $180M | $244M | $428M | $833M |
| Net margin | 2.5% | 3.1% | 4.4% | 6.7% |
| EPS (diluted) | $1.46 | $2.03 | $3.61 | $7.16 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | $211M | $326M | $474M | $660M |
| Capital expenditures | $109M | $125M | $171M | $201M |
| Free cash flow | $102M | $201M | $303M | $458M |
| Share buybacks | $34.6M | $35.6M | $152M | $153M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $375M | $370M | $423M | $596M |
| Total assets | — | $5.89B | $5.99B | $7.21B |
| Total liabilities | — | $4.12B | $4.09B | $5.00B |
| Shareholders' equity | $1.68B | $1.77B | $1.90B | $2.22B |
| Retained earnings | — | -$852M | -$424M | $409M |
| Shares (wtd avg diluted) | 124M | 120M | 119M | 116M |
Every figure is extracted from CELESTICA INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.